Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inactive Placebo Oral Capsule Clear all
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 8, 2026, 1:07 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

NCT07678359
View directory record Official record
Conditions
Sleep Quality, Menopause
Interventions
Lotus Seed & Rice Germ Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

NCT01138475
View directory record Official record
Conditions
Gastric Bypass, Parathyroid Hormone
Interventions
Paricalcitol, Cholecalciferol, Placebo
Drug
Lead sponsor
Kerstyn C. Zalesin, M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 8, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)

NCT03221751
View directory record Official record
Conditions
Dementia
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 8, 2026, 1:07 AM EDT
Active, not recruiting Early Phase 1 Interventional

Modafinil and Cognitive Function in POTS

NCT01988883
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo, Modafinil, Propranolol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07601425
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions
ATV-1601, Placebo
Drug
Lead sponsor
Atavistik Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

Preoperative Acetazolamide

NCT07101250
View directory record Official record
Conditions
Post Operative Pain, Laparoscopic Hysterectomy, Referred Pain
Interventions
Acetazolamide 500 MG Extended Release Oral Capsule, Placebo
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional

INvestigating TELmisartin Study

NCT04715763
View directory record Official record
Conditions
Covid19
Interventions
Telmisartan Oral Product, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 8, 2026, 1:07 AM EDT
Not yet recruiting Phase 4 Interventional

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

NCT07369115
View directory record Official record
Conditions
Major Depressive Diorder, Early Life Trauma
Interventions
Lumateperone 42 mg, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults

NCT07322679
View directory record Official record
Conditions
Health Adult Subjects
Interventions
Placebo （Microcrystalline Cellulose）, Dihydroberberine（DHB）
Dietary Supplement
Lead sponsor
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Other
Eligibility
35 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

NCT02371889
View directory record Official record
Conditions
Alcoholism, Alcohol Use Disorder (AUD)
Interventions
Topiramate, Medical Management, Inactive Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

CANVAS - CANagliflozin cardioVascular Assessment Study

NCT01032629
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventions
Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
58
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Neurobiology of Bulimia Nervosa

NCT04225221
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

NCT03315494
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

NCT02008565
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Loperamide, Placebo, Anal exercises with biofeedback, Usual Care
Drug · Behavioral
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 8, 2026, 1:07 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

NCT00483548
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
60
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

NCT06349083
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin, Inactive Placebo, Supportive therapy sessions
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 8, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

NCT07189754
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Dysfunction, Cognitive Disorder, Memory Problems
Interventions
Sabroxy™ (Oroxylum indicum extract), Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
60 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 8, 2026, 1:07 AM EDT